Short-seller Citron targets PLTR again, using a Databricks comparison to argue the stock is overvalued after its report sent ...

Palantir shares tumbled Tuesday afternoon, extending recent losses as a high-profile short seller fueled worries the stock ...

Andrew Left of Citron Research, which rose to fame for their role in exposing Valeant Pharmaceuticals, has taken to X to voice his concerns over the ruling in the Trump trial. Using Citron ...

Citron Reseach’s founder Andrew Left, who once said crypto is “complete fraud,” is now facing fraud charges after the SEC accused him of profiting $16 million from market manipulation.

Left's other company, Citron Research, on May 17, 2019, issued a negative tweet on Beyond Meat, which recommended that readers sell the stock and assign it a target price of $65 per share, at a ...

This Pure-Play Artificial Intelligence (AI) Stock Is Up 140% This Year but Trades at an Unsustainable Level, According to ...

Citron Research founder Andrew Left analyzes the state of the U.S. market and the wider economy on 'The Claman Countdown.' ...